Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LIPA | P38571 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | TLR4 | O00206 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14877974 | 0.93 | NAMPT (0.33) | NAMPTP2RX7ALDH1A1EPHX1NPC1 | |
| SCHEMBL14146038 | 0.91 | EPHX1 (0.34) | NAMPTP2RX7ALDH1A1EPHX1NPC1 | |
| SCHEMBL15043693 | 0.89 | LIPA (0.38) | NAMPTALDH1A1EPHX1LIPAAKR1C3 | |
| SCHEMBL14576723 | 0.89 | LIPA (0.38) | NAMPTALDH1A1EPHX1LIPAAKR1C3 | |
| SCHEMBL526891 | 0.89 | — | — | |
| SCHEMBL14571162 | 0.86 | TLR4 (0.38) | NAMPTEPHX1TLR4 | |
| SCHEMBL1300955 | 0.82 | NAMPT (0.37) | NAMPTP2RX7ALDH1A1EPHX1NPC1 | |
| SCHEMBL15043694 | 0.82 | KMT2A (0.40) | NAMPTALDH1A1EPHX1NPC1LIPA | |
| SCHEMBL503733 | 0.80 | ANPEP (0.47) | NAMPTP2RX7ALDH1A1EPHX1NPC1 | |
| SCHEMBL12424289 | 0.80 | ESR1 (0.33) | NAMPTALDH1A1EPHX1LIPAAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353223-B2 | Polyamic acid, polyimide, polyamic acid solution, and use of polyimide | KANEKA CORPORATION (JP) | 2016-05-31 | — | — | US | disclosed |
| US-9187477-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | SEATTLE GENETICS, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150183931-A1 | POLYAMIC ACID, POLYIMIDE, POLYAMIC ACID SOLUTION, AND USE OF POLYIMIDE | KANEKA CORPORATION (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20150119393-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-30 | — | — | US | disclosed |
| US-20140343084-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-8815926-B2 | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases | NOVARTIS AG (CH) | 2014-08-26 | — | — | US | disclosed |
| US-20140011798-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2014-01-09 | — | — | US | disclosed |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | Bayer Pharma AG (DE) | 2013-04-18 | — | — | US | disclosed |
| US-8420145-B2 | Isosorbide derivatives and their use as flavor modifiers, tastants, and taste enhancers | SENOMYX, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2011-06-09 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| EP-1385870-B1 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| WO-2008003861-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2008-01-10 | — | — | WO | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011798-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | MDM4, MDM2, TP53 | NAMPT 1791/4885P2RX7 4574/4885ALDH1A1 2047/4885 |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | NAMPT 2531/4885P2RX7 2622/4885ALDH1A1 2369/4885 |
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | EPX, PGLS, ENPEP | NAMPT 698/4885P2RX7 3625/4885ALDH1A1 1233/4885 |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | NAMPT 2531/4885P2RX7 2622/4885ALDH1A1 2369/4885 |
| US-20150119393-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | PRKAR2B, PRKAB2, PRKAB1 | NAMPT 1145/4885P2RX7 884/4885ALDH1A1 1229/4885 |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | DDR1, IGFBP6, KDR | NAMPT 1453/4885P2RX7 4880/4885ALDH1A1 2838/4885 |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | CDK4, CDKL4, FLT4 | NAMPT 852/4885P2RX7 4782/4885ALDH1A1 2357/4885 |
| US-20140343084-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | MDM4, MDM2, TP53 | NAMPT 1791/4885P2RX7 4574/4885ALDH1A1 2047/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | NAMPT 2531/4885P2RX7 2622/4885ALDH1A1 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.